A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Pancreatic Cancer
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic or unresectable or recurrent. 2) Only subjects with positive mesothelin expression (Ventana mesothelin [MSLN]- immunohistochemistry [IHC]; Negative=H-score =< 10) are eligible. 3) Patients must have received and either progressed or been intolerant to at least 1 systemic therapy. 4) Life expectancy of at least 3 months.
You may not be eligible for this study if the following are true:
-
1) Participation in another clinical study with an investigational product during the last 28 days or 5 half-lives prior to study Day 1, whichever is shorter. 2) Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression. 3) Any major surgery within 4 weeks of study drug administration.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.